ReviewFrontiers in endocrinology2022
Advances in Knowledge and Management of Immune-Related Adverse Events in Cancer Immunotherapy.
Review in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Neutrophil-to-lymphocyte ratio as a predictive biomarker for hyperprogressive disease mediated by immune checkpoint inhibitors: a systematic review and meta-analysis.Frontiers in immunology · 2024Pooled it
- Observational
- Drug-associated cytokine release syndrome: a FAERS pharmacovigilance study with complementary transcriptomic analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Risk modifiers of immune-related adverse events in patients with NSCLC undergoing immunotherapy: a retrospective cohort study.Journal of pharmaceutical health care and sciences · 2026Article
- Type 2 immunity links eczematous and lichenoid eruptions caused by immune checkpoint inhibitors.Journal of the American Academy of Dermatology · 2025Article
- A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine.Biomolecules · 2025Review
- [Management of immune-related adverse events].Urologie (Heidelberg, Germany) · 2025Review
- Prognostic Features and Potential for Immune Therapy in Metastatic Mismatch Repair-Deficient Colorectal Cancer: A Retrospective Analysis of a Large Consecutive Population-Based Patient Series.Cancer medicine · 2025Article
- Novel Strategies for the Treatment of Lung Cancer: An In-depth Analysis of the Use of Immunotherapy, Precision Medicine, and Artificial Intelligence to Improve Prognoses.Current medicinal chemistry · 2025Review
- Case Report: Tislelizumab-induced panuveitis: a report of two cases.Frontiers in pharmacology · 2025Article
- Cytokine release syndrome caused by immune checkpoint inhibitors: a case report and literature review.Future science OA · 2024Article
- Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study.Acta oncologica (Stockholm, Sweden) · 2024Article
- Into the storm: the imbalance in the yin-yang immune response as the commonality of cytokine storm syndromes.Frontiers in immunology · 2024Review
- A watch-and-wait approach for metachronous multiple colon cancer following neoadjuvant immunotherapy: a case report.Frontiers in immunology · 2024Article
- The Evolving Landscape of Biomarkers for Immune Checkpoint Blockade in Genitourinary Cancers.Biomarker insights · 2024Review
- Corticosteroids and Cancer Immunotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Review
- Baseline Neutrophil-to-Eosinophil Ratio Is Associated with Outcomes in Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.The oncologist · 2023Article
- Review
- Immune-related adverse events of immune checkpoint inhibitors: a review.Frontiers in immunology · 2023Review
- Evaluation of Knowledge of Immunotherapy Toxicities Among Emergency Physicians in Riyadh, Saudi Arabia.Cureus · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-oncologic (IO) therapy has revolutionized the treatment and management of oncologic disease. Immunotherapy functions by enhancing the host immune-systems ability to endogenously clear malignant cells, however, this activation can also lead to immune-mediated damage to healthy native tissues. These side effects are known as immune-related adverse events or irAEs and can even present with phenotypes similar to autoimmune diseases. IrAEs are the major consequence of checkpoint inhibitors and can have a significant impact on a patient's cancer treatment and long-term quality of life. The management of these irAEs follows a similar approach to autoimmune diseases. More specifically, the management is akin to that of autoimmune disease exacerbations. While there is an array of immune-suppressing agents that can be used, steroids, immunomodulators and IO discontinuation are cornerstones of irAE management. The exact approach and dosing are based on the severity and subtype of irAE presented. Within recent years, there has been a push to better prevent and manage irAEs when they arise. There has been an additional effort to increase the number of steroid-sparing agents available for irAE treatment given the consequences of long-term steroid therapy as well as patient contraindications to steroids. The goals of this review are to summarize irAE management, highlight significant advances made in recent years and emphasize the future directions that will optimize the use of IO therapy in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.